Patents by Inventor Nicholas James Devereux

Nicholas James Devereux has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolo[5,1b]oxazole Derivatives as CRF-1 Receptor Antagonists
    Publication number: 20120295942
    Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Application
    Filed: January 28, 2011
    Publication date: November 22, 2012
    Inventors: Nicholas James Devereux, Jeffrey McKenna
  • Pyrazine derivatives as ENAC blockers
    Patent number: 8236808
    Abstract: A compound of Formula I or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Grant
    Filed: June 8, 2009
    Date of Patent: August 7, 2012
    Assignee: Novartis AG
    Inventors: Stephen Paul Collingwood, Nicholas James Devereux, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt
  • Pyrazolo[5,1b]oxazole derivatives as CRF-receptor antagonists
    Patent number: 8163785
    Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives of Formula I: which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 24, 2012
    Assignee: Novartis AG
    Inventors: Nicholas James Devereux, Jeffrey McKenna
  • CYCLOHEXYL AMIDE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS
    Publication number: 20110201629
    Abstract: There are described cyclohexyl amide derivatives of Formula I, which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 18, 2011
    Inventors: Benjamin Atkinson, David Beattie, Andrew James Culshaw, James Dale, Nicholas James Devereux, Jeffrey McKenna
  • Organic Comopunds
    Publication number: 20110201625
    Abstract: A compound of Formula I or a hydrate or solvate thereof, where R1, R2, R3, R4, R5, R6, R7, R8, R9, and R10 have the meanings as indicated in the specification, is useful for treating diseases which respond to the blockade of the epithelial sodium channel. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.
    Type: Application
    Filed: June 8, 2009
    Publication date: August 18, 2011
    Inventors: Stephen Paul Collingwood, Nicholas James Devereux, Catherine Howsham, Peter Hunt, Thomas Anthony Hunt
  • Organic compounds
    Patent number: 7994203
    Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Grant
    Filed: August 3, 2009
    Date of Patent: August 9, 2011
    Assignee: Novartis AG
    Inventors: Ian Bruce, Andrew James Culshaw, Nicholas James Devereux, François Gessier, Jeffrey McKenna, James Neef, Helen Elizabeth Oakman
  • PYRAZOLO[5,1B]OXAZOLE DERIVATIVES AS CRF-1 RECEPTOR ANTAGONISTS
    Publication number: 20110190360
    Abstract: There are described 4-difluoromethoxyphenyl pyrazolo[5.1-b]oxazole derivatives of Formula I: which are useful as corticotropin releasing factor (CRF) receptor antagonists and as pharmaceuticals.
    Type: Application
    Filed: January 31, 2011
    Publication date: August 4, 2011
    Inventors: Nicholas James Devereux, Jeffrey McKenna
  • QUINUCLIDINE DERIVATIVES BINDING TO MUCARINIC M3 RECEPTORS
    Publication number: 20100041887
    Abstract: Compounds of formula I in salt or zwitterionic form wherein, wherein R1, R2, R3, and R4 have the meanings as indicated in the specification, are useful for treating conditions that are mediated by the muscarinic M3 receptor. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.
    Type: Application
    Filed: October 20, 2009
    Publication date: February 18, 2010
    Inventors: Stephen Paul Collingwood, Brian Cox, Urs Baettig, Gurdip Bhalay, Nicholas James Devereux
  • Organic compounds
    Publication number: 20100035874
    Abstract: There are described pyrazolo[5.1-b]oxazole derivatives useful as corticotropin releasing factor (CRF1) receptor antagonists.
    Type: Application
    Filed: August 3, 2009
    Publication date: February 11, 2010
    Inventors: Ian Bruce, Andrew James Culshaw, Nicholas James Devereux, François Gessier, Jeffrey Mc Kenna, James Neef, Helen Elizabeth Oakman